Edwards Lifesciences (EW) FCF Margin (2009 - 2026)

Edwards Lifesciences' FCF Margin history runs 18 years deep, the most recent figure standing at 1.28% for Q1 2026.

• On a quarterly basis, FCF Margin fell 1716.0% year-over-year to 1.28% in Q1 2026; TTM through Mar 2026 was 17.28%, a 582.0% increase from a year earlier, with the FY2025 full-year figure at 22.0%, up 1667.0% from the prior year.
• FCF Margin retreated to 1.28% in Q1 2026 per EW's latest filing, from 22.52% in the prior quarter.
• Across five years, FCF Margin topped out at 49.76% in Q4 2022 and bottomed at 12.79% in Q4 2024.
• The 5-year median for FCF Margin is 18.95% (2022), against an average of 15.62%.
• Across the five-year window, FCF Margin tumbled 4594 bps in 2023 and jumped 3532 bps in 2025, its largest moves.
• Year by year, FCF Margin stood at 49.76% in 2022, then slumped by 92 bps to 3.81% in 2023, then sank by 435 bps to 12.79% in 2024, then surged by 276 bps to 22.52% in 2025, then sank by 106 bps to 1.28% in 2026.
• Per Business Quant, the three latest EW FCF Margin figures stand at 1.28% (Q1 2026), 22.52% (Q4 2025), and 33.24% (Q3 2025).